BR9712283A - Método para inibir as cinases de proteìnas ativadas por tensão - Google Patents

Método para inibir as cinases de proteìnas ativadas por tensão

Info

Publication number
BR9712283A
BR9712283A BR9712283-1A BR9712283A BR9712283A BR 9712283 A BR9712283 A BR 9712283A BR 9712283 A BR9712283 A BR 9712283A BR 9712283 A BR9712283 A BR 9712283A
Authority
BR
Brazil
Prior art keywords
protein kinases
activated protein
inhibiting
tension
inhibiting tension
Prior art date
Application number
BR9712283-1A
Other languages
English (en)
Inventor
Xinkang Wang
Tian-Li Yue
Original Assignee
Boehringer Mannheim Pharm Corp
Smithkline Beecham Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Pharm Corp, Smithkline Beecham Corp Ltd filed Critical Boehringer Mannheim Pharm Corp
Publication of BR9712283A publication Critical patent/BR9712283A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

''MéTODO PARA INIBIR AS CINASES DE PROTEìNAS ATIVADA POR TENSãO'' Método para inibir cinases de proteínas ativadas por tensão (SAPKs) que compreende administrar a um mamífero que dela necessita uma quantidade eficaz de um composto que é uma antaganista dual não-seletivo do adrenorrecptor › e do adenorreceptor <244>~ 1~.
BR9712283-1A 1996-10-09 1997-10-09 Método para inibir as cinases de proteìnas ativadas por tensão BR9712283A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2845996P 1996-10-09 1996-10-09
PCT/US1997/018272 WO1998015272A1 (en) 1996-10-09 1997-10-09 Method for inhibiting stress-activated protein kinases

Publications (1)

Publication Number Publication Date
BR9712283A true BR9712283A (pt) 1999-08-31

Family

ID=21843560

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712283-1A BR9712283A (pt) 1996-10-09 1997-10-09 Método para inibir as cinases de proteìnas ativadas por tensão

Country Status (16)

Country Link
US (1) US6214854B1 (pt)
EP (1) EP0946172A4 (pt)
JP (1) JP2002512591A (pt)
KR (1) KR20000048967A (pt)
CN (1) CN1157188C (pt)
AU (1) AU4751897A (pt)
BR (1) BR9712283A (pt)
CA (1) CA2267967A1 (pt)
CZ (1) CZ123099A3 (pt)
IL (1) IL129326A0 (pt)
NO (1) NO991655L (pt)
NZ (1) NZ335080A (pt)
PL (1) PL332638A1 (pt)
TR (1) TR199900762T2 (pt)
WO (1) WO1998015272A1 (pt)
ZA (1) ZA979055B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2393488A1 (en) * 1999-12-07 2001-06-14 Duke University Use of .alpha.1ar subtype-selective drugs in patients with acute myocardial infarction
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AU2003231283A1 (en) * 2002-04-30 2003-11-17 Sb Pharmco Puerto Rico Inc. Carvedilol monocitrate monohydrate
JP2005533822A (ja) * 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド 臭化水素酸カルベジロール
KR101468827B1 (ko) * 2002-06-27 2014-12-03 스미스클라인 비이참 (코르크) 리미티드 카베딜롤 인산염 및(또는) 그의 용매화물, 상응하는 조성물, 및(또는) 치료 방법
CN101039957A (zh) 2003-05-16 2007-09-19 因特缪恩公司 合成的趋化因子受体配体及其使用方法
HRP20130098T1 (hr) 2003-10-14 2013-02-28 F. Hoffmann - La Roche Ag MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US8734850B2 (en) * 2003-11-25 2014-05-27 Flamel Technologies Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
EP1686986A4 (en) * 2003-11-25 2009-05-27 Sb Pharmco Inc CARVEDILOL SALTS, CORRESPONDING COMPOSITIONS, METHODS OF ADMINISTRATION AND / OR TREATMENT
JP2007512350A (ja) * 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール組成物の治療および送達方法
CA2576030A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2015031914A1 (en) * 2013-08-30 2015-03-05 Uti Limited Partnership Store overload-induced calcium release inhibitors and methods for producing and using the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5405863A (en) 1992-12-01 1995-04-11 Smithkline Beecham Corporation Antioxidant cardioprotective use of, and method of treatment using, hydroxycarbazole compounds
US5308862A (en) * 1993-03-05 1994-05-03 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Beecham Corp., Ltd. Partnership No. 1 Use of, and method of treatment using, carbazolyl-(4)-oxypropanolamine compounds for inhibition of smooth muscle cell proliferation
US5393772A (en) * 1993-11-24 1995-02-28 Boehringer Mannheim Pharmaceuticals Corporation Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
US5643915A (en) * 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies

Also Published As

Publication number Publication date
CZ123099A3 (cs) 1999-11-17
US6214854B1 (en) 2001-04-10
IL129326A0 (en) 2000-02-17
JP2002512591A (ja) 2002-04-23
AU4751897A (en) 1998-05-05
KR20000048967A (ko) 2000-07-25
CA2267967A1 (en) 1998-04-16
CN1157188C (zh) 2004-07-14
NO991655D0 (no) 1999-04-08
EP0946172A1 (en) 1999-10-06
NO991655L (no) 1999-06-08
PL332638A1 (en) 1999-09-27
WO1998015272A8 (en) 2000-03-23
ZA979055B (en) 1999-05-10
WO1998015272A1 (en) 1998-04-16
CN1239888A (zh) 1999-12-29
EP0946172A4 (en) 2002-05-22
NZ335080A (en) 2000-04-28
TR199900762T2 (xx) 1999-07-21

Similar Documents

Publication Publication Date Title
BR9712283A (pt) Método para inibir as cinases de proteìnas ativadas por tensão
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
MY125602A (en) Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
BR9809115A (pt) Métodos para tratar inflamação e doenças inflamatórias usando inibidores de padprt
ECSP941135A (es) Antagonistas triciclicos de vasopresina de benzacepina
BR9908857A (pt) Métodos e composições para tratamento, inibição e prevenção de mucosite
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
NO980729D0 (no) Fremganngsmåte for å nedsette syreinnholdet i råolje
PA8443001A1 (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas
BR9809793A (pt) Monoésteres de probucol para o tratamento de doença inflamatória e cardiovascular
BR9804352A (pt) Composição e processo para controlar o crescimento microbiológico.
DE69912279D1 (de) 5-ht1f agonisten
ES2188214T3 (es) Composicion antioxidante que comprende acetil l-carnitina y acido alfa-lipoico.
BR0111196A (pt) Composições e uso das mesmas para tratamento de flavivìrus e pestivìrus
PT884994E (pt) Utilizacoes de adesivo para protese dentaria que contem extracto de aloe
BG103995A (en) Reverse hydroxamate inhibitors of matrix metalloprreverse hydroxamate inhibitors of matrix metallprooteinases teinases
BR9601630A (pt) Uso de uma quantidade eficaz de pelo menos um composto do tipo retinóide e compostos
BR9909138A (pt) Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda
CO5261493A1 (es) Procedimiento y compuestos para la inhibicion de la mrp1
MX9401294A (es) Derivados de azolona sustituida
PT817625E (pt) Composicoes para o tratamento de pele fotodanificada, compreendendo um antagonista de rar-alfa e um retinoide multi-selectivo
PT84823B (pt) Processo para a preparacao de novos derivados de imidazois 1-substituidos com accao inibidora da dopamina-beta-hidroxilase e de composicoes farmaceuticas que os contem
BR0015939A (pt) Sistemas terapêuticos transdérmicos com estabilidade aperfeiçoada e um processo para a sua preparação
DK0769293T3 (da) Anvendelse af mindst en beta-adrenerg agonist som substans P-antagonist
BR9809848A (pt) Composição

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 36 DA LPI